Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy

Area of Science:

• Nanotechnology in Medicine
• Biotechnology
• Oncology

Background:

• Liposomes are versatile drug carriers, with stealth liposomes (PEGylated) showing improved pharmacokinetics.
• Targeted liposomes for cancer therapy face challenges in efficacy and clinical translation.
• Active targeting of liposomes remains a significant hurdle in cancer treatment.

Purpose of the Study:

• To design and evaluate a novel Super Stealth Immunoliposomes (SSIL2) for enhanced targeted cancer therapy.
• To assess the stability and targeting moiety orientation of SSIL2.
• To compare the in vitro and in vivo performance of SSIL2 against conventional liposomes.

Main Methods:

• Development of SSIL2 using a PEG-bi-phospholipids derivative for stable polymer shielding.
• Conjugation of trastuzumab's fragment antigen-binding (Fab'TRZ) to PEG-bi-phospholipids for outward-oriented targeting.
• In vitro evaluation in cancer cell lines and in vivo studies in zebrafish larvae and rodent models.

Main Results:

• SSIL2 demonstrated enhanced stability of the polymer shield and correct outward orientation of the targeting Fab'TRZ.
• Superior in vitro anticancer efficacy and safety profiles were observed for SSIL2 compared to control liposomes.
• In vivo studies confirmed improved safety and anticancer efficacy of SSIL2 in preclinical models.

Conclusions:

• SSIL2 represents a significant advancement in targeted liposome technology for cancer therapy.
• The novel design of SSIL2 overcomes previous limitations in liposome-based drug delivery.
• SSIL2 shows promise for future clinical development in anticancer treatments.